

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

February 5, 2026

Consolidated Financial Results for the Nine Months Ended December 31, 2025 (Under Japanese GAAP)

Company name: SHIMADZU CORPORATION
 Listing: Tokyo Stock Exchange
 Securities code: 7701
 URL: <https://www.shimadzu.co.jp>
 Representative: Yasunori Yamamoto, President and Representative Director
 Inquiries: Hiroshi Ogasawara, General Manager, Finance and Accounting Dept.
 Telephone: +81-75-823-1127
 Scheduled date to commence dividend payments: –
 Preparation of supplementary material on financial results: Yes
 Holding of financial results briefing: Yes (for institutional investors and analysts)

(Yen amounts are rounded down to millions, unless otherwise noted.)

1. Consolidated financial results for the nine months ended December 31, 2025 (from April 1, 2025 to December 31, 2025)

(1) Consolidated operating results (cumulative)

(Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
Nine months ended								
December 31, 2025	398,722	3.8	50,236	6.8	52,983	7.8	39,087	8.1
December 31, 2024	384,296	5.1	47,045	(7.3)	49,158	(7.1)	36,143	(7.5)

Note: Comprehensive income For the nine months ended December 31, 2025: ¥52,937 million [38.9%]
 For the nine months ended December 31, 2024: ¥38,112 million [(19.8)%]

	Basic earnings per share	Diluted earnings per share
Nine months ended	Yen	Yen
December 31, 2025	135.28	–
December 31, 2024	122.94	–

(2) Consolidated financial position

	Total assets	Net assets	Equity-to-asset ratio
As of	Millions of yen	Millions of yen	%
December 31, 2025	690,578	531,452	77.0
March 31, 2025	672,177	498,066	74.1

Reference: Equity
 As of December 31, 2025: ¥531,442 million
 As of March 31, 2025: ¥498,059 million

2. Cash dividends

	Annual dividends per share				
	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Total
	Yen	Yen	Yen	Yen	Yen
Fiscal year ended March 31, 2025	–	26.00	–	40.00	66.00
Fiscal year ending March 31, 2026	–	27.00	–		
Fiscal year ending March 31, 2026 (Forecast)				40.00	67.00

Note: Revisions to the forecast of cash dividends most recently announced: None

* The year-end dividend for the fiscal year ended March 31, 2025 includes 4.00 yen as a commemorative dividend for the 150th founding anniversary.

3. Consolidated earnings forecast for the fiscal year ending March 31, 2026 (from April 1, 2025 to March 31, 2026)

(Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Basic earnings per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
Fiscal year ending March 31, 2026	555,000	3.0	72,000	0.4	72,000	(0.0)	54,000	0.4	186.89

Note: Revisions to the earnings forecast most recently announced: Yes

* For matters related to the above forecast, please refer to page 7, “Consolidated Outlook.”

*** Notes**

(1) Significant changes in the scope of consolidation during the period: None

Newly included: – companies (–)

Excluded: – companies (–)

(2) Adoption of accounting treatment specific to the preparation of quarterly consolidated financial statements: None

(3) Changes in accounting policies, changes in accounting estimates, and restatement

(i) Changes in accounting policies due to revisions to accounting standards and other regulations: None

(ii) Changes in accounting policies due to other reasons: None

(iii) Changes in accounting estimates: None

(iv) Restatement: None

(4) Number of issued shares (common shares)

(i) Total number of issued shares at the end of the period (including treasury shares)

As of December 31, 2025	296,070,227 shares
As of March 31, 2025	296,070,227 shares

(ii) Number of treasury shares at the end of the period

As of December 31, 2025	7,129,740 shares
As of March 31, 2025	7,152,271 shares

(iii) Average number of shares outstanding during the period

Nine months ended December 31, 2025	288,932,075 shares
Nine months ended December 31, 2024	293,980,658 shares

* Review of the Japanese-language originals of the attached quarterly consolidated financial statements by certified public accountants or an audit firm: None

* Proper use of earnings forecasts, and other special matters

1. The consolidated earnings forecast for the fiscal year ending March 31, 2026 that was announced on November 7, 2025 has been revised in this report.

2. The above forecast was calculated based on information available on the date this report was released. Actual results may vary from forecast values, due to various factors in the future. For matters related to the above forecast, please refer to page 7, “(3) Consolidated Outlook” in “1. Operating Results.”

Table of Contents**Index**

1. Operating Results.....	2
(1) Overview of Operating Results for the Period	2
(2) Overview of Financial Status for the Period	7
(3) Consolidated Outlook.....	7
2. Quarterly Consolidated Financial Statements and Significant Notes	8
(1) Quarterly Consolidated Balance Sheets	8
(2) Quarterly Consolidated Statement of Income and Quarterly Consolidated Statement of Comprehensive Income.....	10
(3) Notes on Quarterly Consolidated Financial Statements	12
Notes on Segment Information, Etc.	12
Notes on the Event of Significant Fluctuations in Shareholders' Capital.....	13
Notes on Going-Concern Assumptions	13
Notes on Quarterly Consolidated Statement of Cash Flows	13
3. Supplemental Information	14

1. Operating Results

(1) Overview of Operating Results for the Period

During the nine months ended December 31, 2025, the global economy faced downside risks to economic growth due to the impact of U.S. tariff policies and economic sluggishness due to the stagnation of private demand in China, in addition to geopolitical risks, such as the escalating tensions in Ukraine and the Middle East, resulting in continued uncertainty about the future; however, it remained resilient.

Under these circumstances, in the Analytical & Measuring Instruments segment, we strengthened sales to growth fields such as the government sector and the university market in Europe, the clinical testing market in North America, and the pharmaceutical market in other Asian countries and regions*¹. We also expanded the recurring business such as after-sales services by leveraging the customer base of Zef Scientific, Inc., which operates multi-vendor services*², in addition to actively introducing new products that utilize AI and robotics and improve operability, and working on enhancing solution proposal capabilities. In the Medical Systems segment, we implemented market penetration strategies for new products that combine AI and IoT technologies for image analysis to extend healthy life expectancies and improve work efficiencies of healthcare professionals. In the Industrial Machinery segment, we promoted the strengthening of sales and expansion of the recurring business for turbomolecular pumps for manufacturing equipment, thereby contributing to advanced semiconductor manufacturing, including the generative AI field, through the provision of key components. In the Aircraft Equipment segment, we developed operations by capturing the growing demand for equipment for defense and commercial aircraft.

Given the above, despite being impacted by the appreciation of the yen, Shimadzu posted net sales for the nine months ended December 31, 2025 of 398,722 million yen (a year-on-year increase of 3.8%). Operating profit was 50,236 million yen (a year-on-year increase of 6.8%) due to the increase in net sales and other factors. Ordinary profit was 52,983 million yen (a year-on-year increase of 7.8%), and profit attributable to owners of parent was 39,087 million yen (a year-on-year increase of 8.1%).

*Notes: 1. Other Asian countries and regions: India, Southeast Asia, South Korea, Taiwan
2. Comprehensive after-sales service provided by a single company for the equipment used by customers, regardless of the manufacturer

The operating results for reportable business segments were as follows.

I. Analytical & Measuring Instruments

In the Analytical & Measuring Instruments segment, in Japan, North America, and other Asian countries and regions, mass spectrometer systems and liquid chromatograph systems increased for purposes such as research and development and quality control for the pharmaceutical market. In Europe, there was an increase in sales for measurement of drug concentration in blood and newborn mass screening in the clinical testing market, as well as an increase in sales of mass spectrometer systems for water quality testing in the government sector and the university market. In China, although net sales declined due to a slowdown in the private sector market and delays in bidding procedures in the government sector and the university market, we actively engaged in sales activities to capture demand from the government sector and the university market, supported by government economic support measures.

As a result, the Analytical & Measuring Instruments segment posted net sales of 259,922 million yen (a year-on-year increase of 4.8%), and operating profit of 35,570 million yen (a year-on-year increase of 5.2%) due to the increase in net sales and other factors.

Net sales broken down by major regions are indicated below.

	Consolidated Results for Nine Months of FY 2024 (millions of yen)	Consolidated Results for Nine Months of FY 2025 (millions of yen)	Percent Increase/Decrease (%)	Overview	
Japan	86,599	91,950	6.2	Sales of liquid chromatograph systems and mass spectrometer systems increased for the pharmaceutical and food market. Additionally, gas chromatograph systems increased in the chemical market, and testing machines increased in the electrical machinery market.	
Outside Japan	161,323	167,971	4.1	The overseas sales ratio was 64.6%, down 0.5 pt.	
Major regions	North America	27,846	30,263	8.7	Mass spectrometer systems co-developed with customers at the R&D Center in North America increased in the clinical testing market. There was also a contribution from the results of Zef Scientific, Inc., which operates multi-vendor services.
	Europe	30,349	33,736	11.2	Liquid chromatograph systems and mass spectrometer systems for water quality testing increased for the government sector and the university market. Additionally, gas chromatograph systems increased in the chemical market.
	China	52,699	51,388	(2.5)	In the private market, although sales of mass spectrometer systems for pharmaceuticals increased, the market was affected by a delayed recovery, resulting in a decrease. Although sales for the government sector and the university market decreased due to the effect of delays in bidding procedures, demand for these sector and market increased due to government economic support measures.
	Other Asian countries	35,868	37,965	5.8	In South Korea, sales of liquid chromatograph systems increased for the pharmaceutical market, while in Southeast Asia and South Korea, mass spectrometer systems increased for the government sector and the university and pharmaceutical market.

II. Medical Systems

In the Medical Systems segment, sales increased in Japan, North America, and other Asian countries and regions due to the effect of new products, including fluoroscopy systems equipped with new software that highly support endoscopy procedures and highly competitive new radiography systems. On the other hand, in Europe, sales decreased due to the impact of reduced medical budgets, particularly in Eastern Europe. In China, sales decreased due to the time required for design modifications to comply with changes in national standards while the market is on a recovery trend, and orders are increasing.

As a result, the Medical Systems segment posted net sales of 52,054 million yen (a year-on-year increase of 3.6%), and operating profit of 2,457 million yen (a year-on-year increase of 49.2%) due to the increase in net sales and other factors.

Net sales broken down by major regions are indicated below.

	Consolidated Results for Nine Months of FY 2024 (millions of yen)	Consolidated Results for Nine Months of FY 2025 (millions of yen)	Percent Increase/Decrease (%)	Overview	
Japan	22,763	23,058	1.3	Sales increased due to the effect of new products, including radiography systems that have enhanced operability through automation and fluoroscopy systems.	
Outside Japan	27,495	28,996	5.5	The overseas sales ratio was 55.7%, up 1.0 pt.	
Major regions	North America	7,672	8,913	16.2	Sales of fluoroscopy systems equipped with new software that highly support endoscopy procedures and radiography systems increased due to the effect of new products.
	Europe	3,505	2,757	(21.3)	Sales of angiography systems and fluoroscopy systems decreased due to the impact of reduced medical budgets, particularly in Eastern Europe.
	China	2,922	2,903	(0.7)	The time required for design modifications to comply with changes in national standards resulted in a decrease in sales of angiography systems.
	Other Asian countries	6,225	7,371	18.4	Sales increased, particularly for fluoroscopy systems, being valued for their low radiation dose and high-quality images.

III. Industrial Machinery

In the Industrial Machinery segment, sales of turbomolecular pumps increased in North America, Europe and China, driven by steady demand for advanced semiconductor manufacturing equipment in the AI field and by demand for coating equipment. Additionally, the recurring business expanded in China and other Asian countries and regions. Sales of hydraulic equipment increased in Japan due to the growing demand for hydraulic units for labor-saving machinery in special-purpose vehicles, despite a decrease for industrial vehicles in North America. Demand for industrial furnaces for automotive ceramics manufacturing decreased in Japan and China due to the decline in demand for electric vehicles.

As a result, the Industrial Machinery segment posted net sales of 51,798 million yen (a year-on-year decrease of 3.1%), and operating profit of 8,121 million yen (a year-on-year increase of 3.0%) due to profitability improvement associated with the growth of the recurring business, among other factors.

Net sales broken down by major regions are indicated below.

	Consolidated Results for Nine Months of FY 2024 (millions of yen)	Consolidated Results for Nine Months of FY 2025 (millions of yen)	Percent Increase/Decrease (%)	Overview	
Japan	22,950	19,737	(14.0)	Sales of turbomolecular pumps for use in semiconductor manufacturing equipment and sales of industrial furnaces for automotive ceramics manufacturing decreased. Sales of hydraulic equipment increased due to the growing demand for hydraulic units for labor-saving machinery in special-purpose vehicles.	
Outside Japan	30,487	32,060	5.2	The overseas sales ratio was 61.9%, up 4.8 pt.	
Major regions	North America	6,328	6,086	(3.8)	Although sales of turbomolecular pumps for use in semiconductor manufacturing equipment increased, sales of hydraulic equipment decreased due to a delayed market recovery for industrial vehicles.
	Europe	3,218	3,511	9.1	Sales of turbomolecular pumps for use in semiconductor manufacturing equipment increased.
	China	14,470	15,350	6.1	Although sales of industrial furnaces for automotive ceramics manufacturing decreased, sales of turbomolecular pumps for use in semiconductor manufacturing equipment and coating equipment increased.
	Other Asian countries	6,341	6,918	9.1	Sales of the recurring business for turbomolecular pumps in Taiwan and South Korea increased.

IV. Aircraft Equipment

In the Aircraft Equipment segment, in Japan, sales for the defense field increased driven by a government policy of strengthening defense. Overseas, in the commercial aircraft equipment field, sales increased due to increased sales of equipment for commercial aircraft and spare parts for airline companies in line with the increase in air passenger demand.

As a result, the Aircraft Equipment segment posted net sales of 30,229 million yen (a year-on-year increase of 8.0%), and operating profit of 5,968 million yen (a year-on-year increase of 46.7%) due to the increase in net sales and other factors.

Net sales broken down by major regions are indicated below.

	Consolidated Results for Nine Months of FY 2024 (millions of yen)	Consolidated Results for Nine Months of FY 2025 (millions of yen)	Percent Increase/Decrease (%)	Overview
Japan	21,999	24,186	9.9	In the defense field, sales of aircraft equipment increased driven by a government policy of strengthening defense.
Outside Japan	5,989	6,042	0.9	The overseas sales ratio was 20.0%, down 1.4 pt.
Major regions North America	5,470	5,398	(1.3)	Although there was increased demand for equipment for commercial aircraft and spare parts for airline companies, sales decreased due to exchange rate effects.

V. Other

Other business segments posted net sales of 4,718 million yen (a year-on-year increase of 0.6%), and operating profit of 775 million yen (a year-on-year increase of 76.3%).

(2) Overview of Financial Status for the Period

As of December 31, 2025, while notes and accounts receivable - trade, and contract assets decreased by 4,617 million yen compared to the end of the previous year, inventories increased by 15,514 million yen, investment securities increased by 5,017 million yen, and cash and deposits increased by 2,269 million yen. Consequently, total assets increased by 18,401 million yen to 690,578 million yen. Liabilities decreased by 14,984 million yen to 159,125 million yen, reflecting decreases of 7,845 million yen in notes and accounts payable - trade and 6,932 million yen in provision for bonuses. Net assets increased by 33,385 million yen to 531,452 million yen, reflecting increases of 19,489 million yen in retained earnings and 12,569 million yen in foreign currency translation adjustment.

(3) Consolidated Outlook

The future outlook is expected to remain uncertain with a continuation of various challenges affecting the economy, such as the impact of U.S. tariff policies and stagnation of private demand in China. In this business environment, we will continue to focus on growth fields and strive to improve our performance.

We have reviewed our consolidated earnings forecast announced on November 7, 2025. Reflecting the depreciation of the yen compared to the exchange rate assumptions of the previous earnings forecast, we will revise our net sales forecast upward. On the other hand, although operating profit is expected to be boosted by increased net sales, we anticipate increases in M&A-related expenses, R&D investments, and other costs aimed at achieving medium- to long-term growth and strengthening competitiveness. Therefore, we maintain the previous forecast for operating profit and the other profit categories.

(Millions of yen)

	Previous Forecast (A)	Revised Forecast (B)	Increase/ Decrease (B-A)	Percent Increase/ Decrease (%)	(Reference) Results for the Previous Fiscal Year
Net Sales	545,000	555,000	10,000	1.8	539,047
Operating Profit	72,000	72,000	–	–	71,720
Ordinary Profit	72,000	72,000	–	–	72,018
Profit Attributable to Owners of Parent	54,000	54,000	–	–	53,776

Note: The forecasted results above were calculated based on information available on the date this report was released. Actual results may vary from forecast values, due to various factors in the future.

2. Quarterly Consolidated Financial Statements and Significant Notes

(1) Quarterly Consolidated Balance Sheets

(Millions of yen)

	As of March 31, 2025	As of December 31, 2025
Assets		
Current assets		
Cash and deposits	143,414	145,684
Notes and accounts receivable - trade, and contract assets	149,127	144,509
Merchandise and finished goods	81,680	88,905
Work in process	27,568	34,409
Raw materials and supplies	34,107	35,554
Other	20,320	19,579
Allowance for doubtful accounts	(1,760)	(1,798)
Total current assets	454,457	466,844
Non-current assets		
Property, plant and equipment		
Buildings and structures, net	55,499	55,678
Machinery, equipment and vehicles, net	10,254	11,533
Land	22,050	22,151
Leased assets, net	1,744	1,729
Construction in progress	3,181	2,358
Other, net	26,829	28,057
Total property, plant and equipment	119,559	121,510
Intangible assets		
Goodwill	7,779	7,546
Other	15,964	17,598
Total intangible assets	23,744	25,144
Investments and other assets		
Investment securities	15,182	20,199
Long-term loans receivable	233	211
Retirement benefit asset	41,177	41,810
Deferred tax assets	12,247	9,391
Other	5,623	5,533
Allowance for doubtful accounts	(49)	(66)
Total investments and other assets	74,416	77,078
Total non-current assets	217,719	223,733
Total assets	672,177	690,578

(Millions of yen)

	As of March 31, 2025	As of December 31, 2025
Liabilities		
Current liabilities		
Notes and accounts payable - trade	47,634	39,788
Short-term borrowings	1,368	867
Lease liabilities	3,535	4,179
Accounts payable - other	16,277	18,619
Income taxes payable	8,875	3,460
Contract liabilities	46,206	43,945
Provision for bonuses	14,044	7,111
Provision for bonuses for directors (and other officers)	378	248
Provision for share awards	35	100
Provision for recall	1,243	882
Other	11,689	16,081
Total current liabilities	151,288	135,285
Non-current liabilities		
Long-term borrowings	4	–
Lease liabilities	6,840	6,879
Provision for retirement benefits for directors (and other officers)	131	137
Retirement benefit liability	13,509	14,572
Provision for share awards	70	–
Other	2,263	2,249
Total non-current liabilities	22,821	23,839
Total liabilities	174,110	159,125
Net assets		
Shareholders' equity		
Share capital	26,648	26,648
Capital surplus	34,910	34,910
Retained earnings	411,717	431,207
Treasury shares	(26,113)	(26,069)
Total shareholders' equity	447,163	466,697
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	5,158	7,493
Foreign currency translation adjustment	28,055	40,625
Remeasurements of defined benefit plans	17,681	16,626
Total accumulated other comprehensive income	50,895	64,744
Non-controlling interests	7	10
Total net assets	498,066	531,452
Total liabilities and net assets	672,177	690,578

(2) Quarterly Consolidated Statement of Income and Quarterly Consolidated Statement of Comprehensive Income
Quarterly Consolidated Statement of Income

(Millions of yen)

	Nine months ended December 31, 2024	Nine months ended December 31, 2025
Net sales	384,296	398,722
Cost of sales	217,764	219,400
Gross profit	166,532	179,322
Selling, general and administrative expenses	119,487	129,086
Operating profit	47,045	50,236
Non-operating income		
Interest income	1,112	1,062
Dividend income	318	282
Insurance claim income	78	134
Subsidy income	511	475
Foreign exchange gains	726	1,921
Other	502	542
Total non-operating income	3,251	4,419
Non-operating expenses		
Interest expenses	231	219
Donations	115	382
Other	790	1,069
Total non-operating expenses	1,137	1,672
Ordinary profit	49,158	52,983
Extraordinary income		
Gain on sale of non-current assets	222	191
Gain on change in equity	47	-
Total extraordinary income	270	191
Extraordinary losses		
Loss on disposal of non-current assets	174	227
Loss on valuation of investment securities	2	-
Total extraordinary losses	176	227
Profit before income taxes	49,251	52,948
Income taxes - current	10,950	11,157
Income taxes - deferred	2,158	2,703
Total income taxes	13,109	13,860
Profit	36,142	39,087
Loss attributable to non-controlling interests	(0)	(0)
Profit attributable to owners of parent	36,143	39,087

Quarterly Consolidated Statement of Comprehensive Income

(Millions of yen)

	Nine months ended December 31, 2024	Nine months ended December 31, 2025
Profit	36,142	39,087
Other comprehensive income		
Valuation difference on available-for-sale securities	(1,481)	2,334
Foreign currency translation adjustment	4,341	12,569
Remeasurements of defined benefit plans, net of tax	(890)	(1,054)
Total other comprehensive income	1,969	13,849
Comprehensive income	38,112	52,937
Comprehensive income attributable to		
Comprehensive income attributable to owners of parent	38,112	52,937
Comprehensive income attributable to non-controlling interests	(0)	(0)

(3) Notes on Quarterly Consolidated Financial Statements**Notes on Segment Information, Etc.**

1) Segment Information

I From April 1 to December 31 of fiscal year ended March 31, 2025

Information on net sales and profit (loss) by reportable segment

(Millions of yen)

	Reportable segment					Other (Note 1)	Total	Adjust- ments (Note 2)	Amounts reported on the quarterly consoli- dated statement of income (Note 3)
	Analytical & Measuring Instruments	Medical Systems	Industrial Machinery	Aircraft Equipment	Total				
Net sales									
Sales to customers	247,923	50,258	53,437	27,988	379,608	4,688	384,296	–	384,296
Inter-segment sales	27	14	61	30	133	1,761	1,894	(1,894)	–
Total	247,950	50,273	53,499	28,018	379,741	6,449	386,191	(1,894)	384,296
Operating profit	33,823	1,647	7,886	4,067	47,424	440	47,864	(819)	47,045

Notes: 1. The “Other” category is a business segment that is not included in the reportable segments. It includes businesses such as real estate rental, real estate management, and construction flooring.

2. An adjustment to segment operating profit of (819) million yen consists primarily of testing and research expenses of (818) million yen that are not allocated to the reportable segments.

3. Segment operating profit is reconciled to operating profit in the quarterly consolidated statement of income.

II From April 1 to December 31 of fiscal year ending March 31, 2026

Information on net sales and profit (loss) by reportable segment

(Millions of yen)

	Reportable segment					Other (Note 1)	Total	Adjust- ments (Note 2)	Amounts reported on the quarterly consoli- dated statement of income (Note 3)
	Analytical & Measuring Instruments	Medical Systems	Industrial Machinery	Aircraft Equipment	Total				
Net sales									
Sales to customers	259,922	52,054	51,798	30,229	394,004	4,718	398,722	–	398,722
Inter-segment sales	38	18	46	8	112	1,757	1,869	(1,869)	–
Total	259,960	52,073	51,844	30,237	394,116	6,475	400,592	(1,869)	398,722
Operating profit	35,570	2,457	8,121	5,968	52,117	775	52,893	(2,657)	50,236

Notes: 1. The “Other” category is a business segment that is not included in the reportable segments. It includes businesses such as real estate rental, real estate management, and construction flooring.

2. An adjustment to segment operating profit of (2,657) million yen consists primarily of testing and research expenses and core system-related expenses of (2,657) million yen that are not allocated to the reportable segments.

3. Segment operating profit is reconciled to operating profit in the quarterly consolidated statement of income.

2) Related Information

Information on the Amount of Net Sales by Geographical Segment

From April 1 to December 31 of fiscal year ended March 31, 2025

						(Millions of yen)
Japan	The Americas	Europe	China	Other Asian countries	Other	Total
158,996	55,614	37,313	70,154	48,651	13,566	384,296

From April 1 to December 31 of fiscal year ending March 31, 2026

						(Millions of yen)
Japan	The Americas	Europe	China	Other Asian countries	Other	Total
163,647	59,422	40,394	69,796	52,348	13,114	398,722

Note: Main countries and regions included in the geographical segments other than Japan

The Americas: U.S.A.

Europe: U.K., Germany

China: China

Other Asian countries: India, Southeast Asia, South Korea, Taiwan

Other: Australia, Middle East, Africa

Notes on the Event of Significant Fluctuations in Shareholders' Capital

Not applicable.

Notes on Going-Concern Assumptions

Not applicable.

Notes on Quarterly Consolidated Statement of Cash Flows

The Company has not prepared a quarterly consolidated statement of cash flows for the nine months ended December 31, 2025. Amounts of depreciation (including amortization of intangible assets excluding goodwill) and amortization of goodwill are as follows.

			(Millions of yen)
	Nine months ended December 31, 2024	Nine months ended December 31, 2025	
Depreciation and amortization	14,496	15,216	
Amortization of goodwill	640	648	

3. Supplemental Information

Overview of Financial Results for the First Nine Months of the Fiscal Year Ending March 2026

Row No.			Consolidated Results for First Nine Months of FY 2024	Consolidated Results for First Nine Months of FY 2025	Year on Year		FY 2024	FY 2025
			Results	Results	Increase/Decrease	Percent Increase/Decrease	Results	Forecast
1	Net Sales	millions of yen	384,296	398,722	14,426	3.8%	539,047	555,000
2	Net Sales (Analytical & Measuring Instruments)	millions of yen	247,923	259,922	11,998	4.8%	347,915	–
3	Net Sales (Medical Systems)	millions of yen	50,258	52,054	1,795	3.6%	72,567	–
4	Net Sales (Industrial Machinery)	millions of yen	53,437	51,798	(1,639)	(3.1)%	72,335	–
5	Net Sales (Aircraft Equipment)	millions of yen	27,988	30,229	2,240	8.0%	38,662	–
6	Net Sales (Other)	millions of yen	4,688	4,718	29	0.6%	7,566	–
7	Net Sales by Region (Japan)	millions of yen	158,996	163,647	4,651	2.9%	234,565	–
8	Net Sales by Region (Outside Japan)	millions of yen	225,300	235,075	9,774	4.3%	304,482	–
9	Net Sales (The Americas)	millions of yen	55,614	59,422	3,807	6.8%	78,555	–
10	Net Sales (Europe)	millions of yen	37,313	40,394	3,080	8.3%	49,560	–
11	Net Sales (China)	millions of yen	70,154	69,796	(357)	(0.5)%	91,352	–
12	Net Sales (Other Asian Countries)	millions of yen	48,651	52,348	3,696	7.6%	64,975	–
13	Net Sales (Other)	millions of yen	13,566	13,114	(451)	(3.3)%	20,037	–
14	Operating Profit	millions of yen	47,045	50,236	3,190	6.8%	71,720	72,000
15	Ordinary Profit	millions of yen	49,158	52,983	3,825	7.8%	72,018	72,000
16	Profit Attributable to Owners of Parent	millions of yen	36,143	39,087	2,944	8.1%	53,776	54,000
17	Earnings per Share (FY 2025 Q3)	Yen	122.94	135.28	–	–	183.55	186.89
18	Dividend per Share	Yen	26.00	27.00	–	–	66.00	67.00
19	Capital Equipment Investment	millions of yen	17,162	16,888	(273)	(1.6)%	22,949	25,000
20	Depreciation and Amortization	millions of yen	14,496	15,216	720	5.0%	19,895	20,000
21	Total Assets	millions of yen	658,241	690,578	32,336	4.9%	672,177	–
22	Net Assets	millions of yen	491,458	531,452	39,994	8.1%	498,066	–
23	Equity-to-Asset Ratio	%	74.7	77.0	–	–	74.1	–
24	Number of All Group Employees	Employees	14,519	14,697	178	–	14,481	–
25	Number of Consolidated Subsidiaries	Companies	81	77	–	–	81	–
26	Japan	Companies	23	21	–	–	23	–
27	Outside Japan	Companies	58	56	–	–	58	–